JGB Futures Edge Lower as Investors Assess Mixed Signals
0009 GMT — JGB futures edge lower in the early Tokyo session as investors assess mixed signals. On the one hand, Japan's sovereign debt will probably be supported by potential safe-haven demand driven by the U.S. strikes on Iran over the weekend. On the other hand, market participants could be concerned over Japanese inflationary pressures that could increase due to the higher oil prices caused by the U.S. attacks. Ten-year JGB futures are 0.14 yen lower at 139.29 yen. (ronnie.harui@wsj.com)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
20 minutes ago
- Bloomberg
What's Next After the Initial Fallout from US Strikes on Iran
What's next? The unprecedented US airstrikes on Iran have set traders and governments worldwide on edge, as the Islamic Republic warns of retaliation and Israel shows no sign of letting up in its assault. Asian currencies and stocks fell, European stock futures declined while oil advanced, then erased gains, after Washington struck Iran's nuclear sites over the weekend. China and Pakistan were quick to condemn — even though China hasn't yet offered substantial assistance to Tehran besides rhetorical support and Pakistan is at the same time taking steps to build stronger ties with the White House. The US State Department issued a ' Worldwide Caution ' alert for Americans. More critically, President Donald Trump's decision to deploy bunker-busting bombs — in Washington's first direct military action against Iran after decades of hostility — has pushed the Middle East into uncharted territory. Did the end justify the means? While the US attacks have set back Iran's nuclear ambitions and dealt its clerical regime a humiliating blow, the program hasn't been completely destroyed. The move may ultimately lead Tehran to end international monitoring of its nuclear program and consider going ahead to develop a bomb. Supreme Leader Ayatollah Ali Khamenei hasn't been seen in public in 11 days but remains in control. Even as diplomatic allies Russia and China have stayed on the sidelines and its network of armed proxies in the region remains weakened, Tehran still has ways to inflict pain on the US as it plans its retaliation. Two supertankers, each capable of hauling about 2 million barrels of crude, U-turned in the Strait of Hormuz after the US airstrikes on Iran raised the risk of a response that would ensnare commercial shipping in the region, according to vessel tracking data compiled by Bloomberg. The two empty freighters then sailed south, away from the mouth of the Persian Gulf. The turning oil carriers offer the first signs of re-routing, something that oil traders will scrutinize. Any disruption to traffic through the strait, a major artery for global crude and natural gas, raises the specter of a spike in energy prices. That's bad news for Asia, which buys more than four-fifths of all the crude produced in the Middle East, 90% of which goes through the Strait of Hormuz.
Associated Press
26 minutes ago
- Associated Press
SenturoPay Launches Comprehensive Crypto Payment Card for Everyday Users
Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) -- SenturoPay, a fast-growing digital finance platform, today announced the official launch of its all-in-one crypto payment card, developed to help users manage and utilize their digital assets in everyday life. With features designed to send, swap, and spend crypto, the platform delivers a real-world solution for individuals looking to simplify how they interact with their crypto holdings. 'This isn't a tech showcase—it's a lifestyle tool,designed with our users' convenience in mind.' said a Co-Founder at SenturoPay. 'We've built a crypto experience that mirrors what users already expect from modern finance—clear, responsive, and practical.' Making Crypto Work for the Real World While crypto adoption continues to expand, many platforms remain focused on trading or storage, leaving users with limited ways to access their assets for real-world needs. SenturoPay fills that gap by offering a comprehensive crypto app and payments system tailored for ease of use and day-to-day functionality. With just a few taps, users can: Everything is managed through a centralized, secure dashboard, giving users full control and visibility over their digital finances. Key Platform Features Designed for Mass Adoption SenturoPay is intentionally built for a wide range of users—from crypto newcomers to digital natives. Its emphasis on clarity, simplicity, and utility sets it apart from platforms that require a steep learning curve or technical fluency. 'We've designed SenturoPay so that anyone—regardless of their crypto background—can access, manage, and use their assets confidently,' added the spokesperson. 'It's about giving people tools that make digital money practical, not just possible.' About SenturoPay SenturoPay is a digital finance platform focused on turning crypto into a usable, everyday financial tool. With a strong emphasis on simplicity, security, and practical use cases, the platform offers users a streamlined way to send crypto, swap tokens, and spend digital assets through one integrated experience. To learn more, visit SenturoPay's official website. Media Team [email protected]
Associated Press
26 minutes ago
- Associated Press
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Jun 23, 2025-- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono') and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, MA, U.S.; CEO: Reshma Kewalramani, M.D.; 'Vertex') today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other serious B cell-mediated diseases. Under the terms of the agreement, Ono will pay Vertex an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. 'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.' 'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure, and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.' The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. View source version on CONTACT: Ono Pharmaceutical Co., Ltd. Corporate Communications [email protected] more information: Vertex Pharmaceuticals Incorporated Investors: [email protected]: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: NORTH AMERICA UNITED STATES SOUTH KOREA ASIA PACIFIC JAPAN MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS SOURCE: Ono Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/23/2025 04:00 AM/DISC: 06/23/2025 04:02 AM
